2015
DOI: 10.4314/mmj.v27i3.7
|View full text |Cite
|
Sign up to set email alerts
|

Supra-treatment threshold neonatal jaundice: Incidence in HIV-exposed compared to non-exposed neonates at Queen Elizabeth Central Hospital in Blantyre, Malawi

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
3
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 4 publications
1
3
0
Order By: Relevance
“…Eight babies in this study developed NNJ and of these, only 1 was HIV-positive -this was a statistically significant finding. The higher incidence of NNJ among the babies of HIV-negative women is in keeping with the findings by Nakanga et al [24] in a study undertaken in Malawi in 2015. They hypothesised that the efavirenz (EFV) in the prevention of mother-to-child transmission (PMTCT) of HIV acted as a fetal liver enzyme inducer that would aid the conjugation of bilirubin.…”
Section: Discussionsupporting
confidence: 90%
“…Eight babies in this study developed NNJ and of these, only 1 was HIV-positive -this was a statistically significant finding. The higher incidence of NNJ among the babies of HIV-negative women is in keeping with the findings by Nakanga et al [24] in a study undertaken in Malawi in 2015. They hypothesised that the efavirenz (EFV) in the prevention of mother-to-child transmission (PMTCT) of HIV acted as a fetal liver enzyme inducer that would aid the conjugation of bilirubin.…”
Section: Discussionsupporting
confidence: 90%
“…This finding is in keeping with a study done in a hospital in Malawi, which showed a higher incidence of jaundice in HIV unexposed neonates as compared to the HIV exposed neonates. One of the possible hypotheses for this finding as postulated by the authors is the use of drugs such as efavirenz, tenofovir, and lamivudine in pregnant and breast-feeding women as part of the prevention of mother-to-child transmission (PMTCT) programme in Malawi Efavirenz may act as a fetal liver enzyme inducer which helps in the conjugation of bilirubin thereby reducing the risk of jaundice in the HIV exposed infants ( 28 ).…”
Section: Discussionmentioning
confidence: 99%
“…Jaundice can be physiological or pathological; physiological jaundice develops in the first week after delivery as a result of increases in bilirubin production due to the destruction of fetal erythrocytes with transient restrictions in conjugated bilirubin, which is often mild and sometimes does not require any treatments. On the other hand, pathological jaundice usually occurs within the first 24 hours or after the first week of birth [5] . In pathological jaundice, increased production of non-conjugated bilirubin decreases hepatic uptake, and increased bilirubin enterohepatic cycle leads to increased non-conjugated bilirubin [6] .…”
Section: Introductionmentioning
confidence: 99%
“…Clinical interventions for jaundice include phototherapy; administration of chemical medications such as phenobarbital; and complete or partial blood exchange transfusion. Given many complications of exchange transfusion in neonates including hypoglycemia, hypocalcemia, the risk of sepsis, thrombocytopenia, and even death [5] , it may be the last choice to reduce bilirubin level in cases of jaundice who do not respond to other treatments [8] . Phototherapy is the most common intervention for the prevention and treatment of severe hyperbilirubinemia [9] .…”
Section: Introductionmentioning
confidence: 99%